NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment

Obinutuzumab (OBZ) shows stronger antibody-dependent cell cytotoxicity (ADCC) compared to rituximab and improved clinical activity for treating certain CD20(+) neoplasia. However, the efficacy of monoclonal antibody (mAb) as a monotherapy is limited. Natural Killer (NK) cells are mediators of ADCC....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Vo, Dang-Nghiem, Alexia, Catherine, Allende-Vega, Nerea, Morschhauser, Franck, Houot, Roch, Menard, Cedric, Tarte, Karin, Cartron, Guillaume, Villalba, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889292/
https://ncbi.nlm.nih.gov/pubmed/29632722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1409322
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados